Androgen deprivation therapy lowers testosterone—or blocks the hormonal pathway that prostate cancer uses for growth. The main testosterone-suppressing approaches are bilateral orchiectomy, gonadotropin-releasing hormone (GnRH/LHRH) agonists, and GnRH antagonists. Androgen deprivation therapy can strengthen radiation treatment in intermediate- and high-risk localized disease, control recurrent or advanced prostate cancer, and form the hormonal backbone of modern metastatic treatment. It is not a neutral treatment: loss of testosterone can affect sexual function, hot flashes, muscle, body fat, bone, metabolism, cardiovascular health, mood and energy.
Androgen deprivation therapy works primarily by reducing testicular testosterone to a castrate range. Current EAU guidance prefers a profound testosterone target below 20 ng/dL when achievable, although the historical regulatory definition of castration remains below 50 ng/dL. GnRH agonists suppress testosterone after an initial hormonal surge; GnRH antagonists suppress it rapidly without flare; bilateral orchiectomy lowers it fastest and permanently. The correct duration depends on why treatment is being used: months with radiation for some intermediate-risk cancers, years with radiation for high-risk disease, or continuous treatment as the backbone of metastatic therapy. In metastatic hormone-sensitive prostate cancer, fit patients generally receive treatment intensification rather than androgen deprivation therapy alone.
01How Does Androgen Deprivation Therapy Work in Prostate Cancer?
Most prostate cancers remain dependent on androgen-receptor signaling
Androgens are hormones that activate the androgen receptor.
The two most important are:
- testosterone;
- and dihydrotestosterone (DHT).
NCI explains that androgens enter prostate cells, bind directly to the androgen receptor or are converted to DHT, which binds even more strongly.
The activated androgen receptor then changes gene expression in ways that support prostate-cell survival and cancer growth.
Where does testosterone come from?
Most circulating testosterone is produced by the testes.
A smaller androgen contribution comes from:
- the adrenal glands;
- and, in advanced prostate cancer, sometimes androgen synthesis within tumor tissue itself.
That is why reducing testicular testosterone is a powerful treatment but does not necessarily eliminate every androgen-receptor signal in advanced cancer.
How does the brain normally control testosterone?
The hormonal pathway is often called the hypothalamic-pituitary-gonadal axis:
- the hypothalamus releases GnRH;
- the pituitary responds by releasing luteinizing hormone (LH);
- LH stimulates the testes;
- the testes produce testosterone;
- testosterone circulates to prostate and other tissues.
What does medical androgen deprivation interrupt?
GnRH agonists and antagonists act at the pituitary.
Their mechanisms differ:
- GnRH agonists initially stimulate the receptor, causing a short LH/testosterone surge, then chronically down-regulate the pathway;
- GnRH antagonists block the receptor immediately and suppress LH/testosterone without the initial flare.
What does orchiectomy interrupt?
Bilateral orchiectomy removes the primary organ producing testosterone.
EAU describes it as:
- rapid;
- inexpensive;
- effective;
- and irreversible.
Castrate testosterone is generally achieved within hours rather than weeks.
What testosterone level is the goal?
Historically, prostate-cancer trials defined castration as serum testosterone below 50 ng/dL.
Current measurement methods show that surgical castration often produces much lower levels. EAU therefore states that a preferred target is:
below 20 ng/dL (0.7 nmol/L).
The historical 50 ng/dL threshold remains relevant because:
- regulatory definitions still use it;
- many clinical trials use it;
- and castration-resistant prostate cancer is conventionally defined by progression despite testosterone below 50 ng/dL.
Androgen deprivation does not mean “zero androgens.” Adrenal and intratumoral androgen pathways remain biologically relevant, which is one reason advanced prostate cancer often requires additional androgen-receptor pathway inhibition beyond testosterone suppression alone.
02What Types of Androgen Deprivation Therapy Are Used?
GnRH agonists are long-established injectable testosterone suppressors
Examples include:
- leuprolide;
- goserelin;
- triptorelin;
- and other depot formulations.
Depending on the formulation, injections can be given:
- monthly;
- every three months;
- every six months;
- or on another approved depot schedule.
Why can a GnRH agonist cause testosterone flare?
The first dose initially stimulates the pituitary.
EAU describes a testosterone surge beginning approximately two to three days after injection and lasting around one week before receptor down-regulation suppresses testosterone.
Castrate levels are usually reached within roughly two to four weeks.
Why can flare matter?
In a patient with advanced symptomatic disease, even a temporary increase in androgen stimulation can theoretically worsen:
- bone pain;
- bladder outlet obstruction;
- ureteric obstruction;
- or spinal-cord compression.
Short-term older-generation antiandrogen treatment can be used around agonist initiation in selected high-risk situations.
Current EAU guidance also emphasizes that the clinical importance of flare is limited for many patients and flare prevention should be targeted rather than assumed necessary for everyone.
How are GnRH antagonists different?
GnRH antagonists block the pituitary receptor immediately.
They therefore:
- lower LH and testosterone rapidly;
- do not create the initial testosterone flare;
- and are especially useful when rapid suppression is clinically important.
Options include:
- degarelix — a monthly injection;
- relugolix — an oral daily GnRH antagonist.
How fast can degarelix work?
EAU reports that most patients achieve castrate testosterone by approximately day three.
What did the HERO trial show for oral relugolix?
HERO randomized 934 men with advanced prostate cancer to oral relugolix or leuprolide for 48 weeks.
Sustained testosterone suppression below 50 ng/dL occurred in:
- 96.7% with relugolix;
- 88.8% with leuprolide.
On day four, castrate testosterone had been reached by:
- 56.0% receiving relugolix;
- 0% receiving leuprolide.
The trial also reported major adverse cardiovascular events in 2.9% versus 6.2%, respectively.
That cardiovascular signal is clinically important but should not be treated as definitive proof that every antagonist is safer for every cardiovascular patient. A broader randomized-trial meta-analysis also suggested fewer cardiovascular events with GnRH antagonists, while noting that the evidence quality remains imperfect.
What is the trade-off of an oral antagonist?
A daily tablet gives:
- rapid onset;
- no injection depot;
- and potentially faster testosterone recovery after stopping.
But daily oral treatment also makes adherence important. Missing tablets is different from having a depot injection already present for several months.
What is bilateral orchiectomy?
Bilateral orchiectomy surgically removes both testicles or removes their testosterone-producing tissue.
EAU describes it as the fastest way to achieve castrate testosterone—usually within less than 12 hours.
Advantages include:
- immediate effect;
- no injection schedule;
- no medication-adherence problem;
- low ongoing treatment cost.
The major limitation is irreversibility.
Is an androgen-receptor inhibitor the same as androgen deprivation therapy?
Not exactly.
Drugs such as:
- enzalutamide;
- apalutamide;
- darolutamide;
- and older drugs such as bicalutamide;
block androgen-receptor signaling rather than directly serving as the main testicular testosterone-suppression method.
Modern advanced-disease regimens often add these agents to the testosterone-suppression backbone.
Similarly, abiraterone suppresses androgen synthesis and is generally used in addition to ongoing castration therapy.
Drug class is only one treatment decision. Route, adherence, cardiovascular history, need for rapid suppression, planned treatment duration, reversibility and cost can all change which form of testosterone suppression is most practical.
03When Is Androgen Deprivation Therapy Used for Prostate Cancer?
Androgen deprivation therapy is used differently in localized, recurrent and metastatic disease
The same drug can have very different treatment intent depending on disease state.
Androgen deprivation therapy may be used:
- temporarily to improve the effectiveness of definitive radiation;
- after recurrence when systemic hormone control is indicated;
- continuously as the hormonal backbone of metastatic treatment;
- or to palliate disease-related symptoms and reduce complications.
Is androgen deprivation therapy routinely used for low-risk localized prostate cancer?
No.
Androgen deprivation therapy alone is not a standard curative treatment for localized low-risk prostate cancer.
Suitable low-risk disease is commonly managed with active surveillance, while definitive local treatment—when needed—uses surgery or radiation.
Why is androgen deprivation therapy combined with radiation?
In selected higher-risk localized cancers, testosterone suppression improves the effect of radiotherapy by:
- reducing androgen-driven tumor signaling;
- shrinking prostate/tumor volume in some patients;
- and treating microscopic cancer beyond the radiation target.
The duration should match risk.
How long is treatment used with unfavorable intermediate-risk radiation?
Current guideline frameworks commonly use approximately:
4–6 months of androgen deprivation therapy.
This is a temporary combined-treatment strategy rather than permanent hormone suppression.
How long is treatment used with high-risk radiation?
High-risk localized prostate cancer usually requires longer treatment.
Guidelines commonly use:
- approximately 18–36 months in AUA/ASTRO frameworks;
- or approximately 2–3 years in current EAU guidance.
The exact duration is individualized because longer androgen suppression can improve cancer control but also prolong toxicity and delay testosterone recovery.
Is androgen deprivation therapy used after prostatectomy?
Not routinely for every patient.
It can be added in specific postoperative settings such as:
- node-positive disease;
- selected biochemical recurrence;
- or salvage radiation where clinical features support combined treatment.
The indication depends on recurrence risk, PSA pattern, pathology, imaging and the planned salvage strategy.
What is the role in biochemical recurrence?
A rising PSA after local treatment does not automatically require immediate lifelong androgen deprivation.
Management depends on:
- PSA doubling time;
- Grade Group;
- time from treatment to recurrence;
- imaging;
- symptoms;
- and whether salvage local treatment remains possible.
Selected lower-risk recurrent patients may be observed or managed with intermittent hormonal strategies; higher-risk recurrence can justify earlier systemic treatment.
What is the role in metastatic hormone-sensitive prostate cancer?
Androgen deprivation therapy remains the essential hormonal backbone.
But modern treatment generally should not stop there.
Current EAU guidance recommends that fit patients with newly diagnosed metastatic hormone-sensitive prostate cancer receive androgen deprivation therapy combined with a life-prolonging systemic agent such as:
- abiraterone + prednisone/prednisolone;
- apalutamide;
- enzalutamide;
- darolutamide;
- or another guideline-supported androgen-receptor pathway regimen.
Selected fit patients also receive docetaxel as part of triplet treatment.
Why is androgen deprivation therapy alone usually insufficient in fit metastatic patients?
Because multiple randomized trials have shown improved survival when modern systemic treatment is added to the testosterone-suppression backbone.
EAU therefore recommends against androgen deprivation monotherapy in newly presenting M1 disease when:
- the patient is fit for combination therapy;
- has sufficient life expectancy to benefit;
- and accepts the additional side-effect burden.
What happens when cancer progresses despite low testosterone?
The disease is assessed for castration-resistant prostate cancer.
By definition, progression must occur despite ongoing castrate testosterone—conventionally below 50 ng/dL.
Testosterone suppression is usually continued while other life-prolonging therapies are added or changed.
| Clinical setting | Role of androgen deprivation therapy | Typical duration / pattern | Key distinction |
|---|---|---|---|
| Low-risk localized | Not routine primary therapy. | Generally none. | Active surveillance or definitive local therapy is preferred when appropriate. |
| Favorable intermediate-risk with radiation | Often omitted. | Usually none unless another indication exists. | Avoid unnecessary hormonal toxicity. |
| Unfavorable intermediate-risk with radiation | Improves combined-treatment efficacy. | Commonly about 4–6 months. | Temporary adjunct to curative-intent radiation. |
| High-risk localized with radiation | Major component of curative multimodal therapy. | Commonly 18–36 months / 2–3 years depending on guideline framework. | Longer exposure increases both cancer benefit and treatment burden. |
| Biochemical recurrence | Risk-adapted systemic control when indicated. | Deferred, intermittent or continuous depending on recurrence risk. | A PSA rise alone does not automatically mean lifelong immediate treatment. |
| Metastatic hormone-sensitive | Essential hormonal backbone. | Generally continuous. | Fit patients usually need treatment intensification beyond monotherapy. |
| Castration-resistant disease | Testosterone suppression is maintained. | Continued. | Additional therapies target cancer that has adapted to the castrate state. |
“Hormone therapy” is not one stage of treatment. A six-month course with curative radiation and continuous castration in metastatic disease use the same biological principle but have different goals, durations and side-effect implications.
04What Are the Side Effects and Long-Term Trade-Offs of Androgen Deprivation Therapy?
The side effects come from removing testosterone’s normal effects throughout the body
Testosterone influences much more than prostate tissue.
It contributes to:
- sexual desire and erectile function;
- muscle mass;
- bone remodeling;
- fat distribution;
- red blood cell production;
- energy and physical performance;
- and aspects of mood and cognition.
Suppressing testosterone therefore creates a whole-body treatment effect.
What sexual changes are common?
Common effects include:
- marked loss of libido;
- erectile dysfunction;
- reduced sexual thoughts and spontaneous erections;
- and decreased sexual activity.
These effects can be compounded when androgen deprivation is combined with prostate radiation or surgery.
Why do hot flashes occur?
Abrupt changes in sex hormones alter hypothalamic temperature regulation.
Hot flashes can range from occasional brief warmth to repeated episodes with sweating and sleep disruption.
How does body composition change?
Androgen deprivation can cause:
- loss of lean muscle mass;
- gain in body fat;
- reduced strength;
- and decreased exercise capacity.
These changes can begin within months and become more important with longer treatment duration.
What metabolic changes occur?
Potential changes include:
- insulin resistance;
- higher glucose;
- changes in cholesterol and triglycerides;
- weight gain;
- and increased risk of diabetes.
EAU therefore recommends ongoing metabolic surveillance, including lipid profiles and HbA1c during long-term therapy.
What happens to bone?
Loss of testosterone accelerates bone loss.
EAU describes increased fracture risk with androgen deprivation and recommends baseline bone-density assessment for men starting long-term treatment.
A review cited by EAU found fracture risk was nearly doubled in some androgen-deprivation populations, with risk increasing according to:
- age;
- treatment duration;
- and additional androgen-receptor pathway treatment.
How is bone health protected?
Risk reduction can include:
- baseline DEXA;
- repeat DEXA according to risk;
- resistance and weight-bearing exercise;
- adequate calcium from diet;
- vitamin D assessment/replacement;
- smoking cessation;
- fall-risk reduction;
- and antiresorptive therapy for osteoporosis or sufficiently high fracture risk.
EAU recommends bone-protective therapy for appropriate high-risk patients and routine surveillance when protective medication is not used.
Does androgen deprivation increase cardiovascular risk?
The relationship is clinically important but complex.
Androgen deprivation can worsen:
- body composition;
- insulin sensitivity;
- lipid profile;
- and other cardiovascular risk factors.
EAU notes that cardiovascular side effects may occur less frequently with GnRH antagonists than agonists and says antagonists may be preferred in patients with pre-existing cardiovascular disease or important risk factors.
However, the evidence is not definitive enough to promise cardiovascular protection simply by changing drug class.
What about fatigue, mood and cognition?
Fatigue is common.
Some patients report:
- lower motivation;
- sleep disturbance;
- mood changes;
- difficulty concentrating;
- or subjective cognitive slowing.
These symptoms can also have other causes—including cancer itself, depression, anemia, sleep disorders and other medications—so a new symptom should not automatically be attributed to testosterone suppression without evaluation.
Can androgen deprivation cause anemia?
Yes.
Testosterone supports red blood cell production, and long-term suppression can reduce hemoglobin.
EAU includes hemoglobin in minimum monitoring for long-term therapy.
Does longer treatment cause more side effects?
Generally, yes.
NCI notes that many adverse effects become more likely or more persistent with longer androgen deprivation.
This is why treatment duration should be long enough to achieve the oncological goal—but not extended automatically without evidence.
| Body system | Possible androgen-deprivation effect | Useful monitoring / mitigation |
|---|---|---|
| Sexual | Low libido, erectile dysfunction. | Pre-treatment counseling, sexual rehabilitation where appropriate, relationship support. |
| Vasomotor | Hot flashes, night sweats. | Symptom review; behavioral or medical treatment when severe. |
| Muscle / body composition | Sarcopenia, fat gain, reduced strength. | Progressive resistance + aerobic exercise, protein/nutrition review, weight monitoring. |
| Bone | Bone mineral-density loss, osteoporosis, fracture. | DEXA, calcium/vitamin D adequacy, exercise, FRAX/risk assessment, antiresorptive therapy when indicated. |
| Metabolic | Insulin resistance, diabetes risk, dyslipidemia. | HbA1c/glucose, lipid profile, blood pressure, healthy weight/diet. |
| Cardiovascular | Potential increase in cardiovascular events, especially in already high-risk patients. | Baseline risk review, optimize BP/lipids/diabetes/smoking; consider drug-class implications. |
| Blood | Reduced hemoglobin / anemia. | Periodic hemoglobin and evaluation of symptomatic anemia. |
| Quality of life | Fatigue, mood changes, cognitive complaints. | Exercise, sleep/mood assessment, treat reversible contributors, supportive care. |
Side-effect prevention should begin when therapy begins—not after osteoporosis, diabetes or severe deconditioning appears. Long-term androgen deprivation requires a survivorship plan alongside the cancer plan.
05How Is Androgen Deprivation Therapy Monitored, and Does Testosterone Recover After Treatment?
PSA alone is not enough
EAU recommends regular clinical follow-up because treatment response and treatment toxicity occur at the same time.
After androgen deprivation begins, follow-up is generally individualized around:
- PSA;
- serum testosterone;
- symptoms;
- treatment adherence;
- metabolic health;
- bone health;
- renal/liver function where relevant;
- and imaging according to disease state.
How often should patients be reviewed?
EAU recommends evaluation approximately every three to six months after treatment initiation, individualized by disease stage, treatment intensity and symptoms.
Patients receiving combination systemic therapy can require more frequent visits early in treatment.
Why should testosterone actually be measured?
It should not be assumed that every medical-castration injection or tablet has achieved the intended testosterone level.
EAU reports that:
- approximately 13–38% of patients can fail to achieve the expected castrate threshold in some series;
- temporary testosterone breakthrough can also occur during long-term medical treatment.
If PSA rises or disease progresses, measuring testosterone is essential before calling the cancer castration resistant.
What happens if testosterone is not adequately suppressed?
Possible responses include:
- confirming the measurement with an appropriate assay;
- checking injection timing or oral adherence;
- switching agonist/antagonist strategy;
- or considering orchiectomy in selected patients.
Does testosterone always recover after temporary treatment?
No.
Recovery is highly variable.
Important predictors include:
- age;
- baseline testosterone;
- treatment duration;
- and type of testosterone-suppression therapy.
How strongly does duration affect recovery?
EAU summarizes a randomized dataset of 1,230 men receiving radiation with different androgen-deprivation durations.
Normal testosterone recovery occurred in:
- 87% with no androgen deprivation;
- 76% after 6 months;
- 55% after 18 months;
- 43% after 36 months.
Time to testosterone recovery also lengthened as treatment duration increased.
This means “temporary” androgen deprivation can have biological effects that last well beyond the final injection.
Does relugolix recover faster than leuprolide?
In the HERO testosterone-recovery subgroup, testosterone above 280 ng/dL by 90 days after treatment discontinuation occurred in:
- 54% after relugolix;
- 3.2% after leuprolide.
Median recovery time was:
- 86 days after relugolix;
- 112 days after leuprolide.
These figures came from a prespecified subgroup and do not guarantee the same recovery for an individual patient.
What should be monitored for long-term toxicity?
Current EAU minimum follow-up for long-term treatment includes:
- medical history focused on treatment complications;
- PSA;
- testosterone;
- hemoglobin;
- creatinine;
- alkaline phosphatase;
- lipid profile;
- HbA1c;
- bone-density assessment;
- and symptom review for metabolic syndrome.
What should happen before long-term treatment begins?
A useful baseline includes:
- weight/BMI and blood pressure;
- cardiovascular history;
- diabetes and lipid status;
- DEXA bone-density scan;
- fracture risk;
- vitamin D/calcium assessment;
- sexual function;
- functional strength and exercise capacity;
- and discussion of expected testosterone recovery if treatment is intended to be temporary.
Can exercise make a meaningful difference?
Yes.
The 2026 ESMO advanced/metastatic prostate-cancer guideline recommends exercise therapy combining:
- aerobic exercise;
- and resistance exercise;
with supervised exercise for at least 12 weeks followed by continued activity.
Exercise is one of the few interventions that can simultaneously address:
- muscle loss;
- fat gain;
- fatigue;
- insulin resistance;
- bone loading;
- and functional independence.
Stopping the drug and recovering testosterone are not the same event. Long depot injections can continue suppressing testosterone after the nominal treatment period, and recovery can take months or years—especially after longer treatment, in older patients or when baseline testosterone was already low.
→Androgen Deprivation Methods at a Glance
| Method | How testosterone is lowered | Speed / flare | Reversibility | Practical trade-off |
|---|---|---|---|---|
| GnRH agonist | Initial pituitary stimulation followed by receptor down-regulation and LH suppression. | Initial testosterone surge; castrate level usually in weeks. | Potentially reversible after depot effect ends. | Long-established depot options; flare matters in selected high-risk advanced disease. |
| Injectable GnRH antagonist | Immediate GnRH-receptor blockade. | Rapid suppression; no flare. | Potentially reversible after treatment stops. | Monthly injections; useful when rapid suppression is important. |
| Oral GnRH antagonist | Immediate receptor blockade with daily oral dosing. | Rapid suppression; no flare. | Potentially reversible, with faster recovery seen in HERO subgroup. | Daily adherence matters; no depot “buffer” after missed doses. |
| Bilateral orchiectomy | Removes the main organ producing testosterone. | Very rapid; no flare. | Permanent. | Simple, reliable and low ongoing cost, but irreversible. |
| AR-pathway drugs added to castration | Block androgen receptor or androgen synthesis beyond testicular suppression. | Not a substitute for adequate testosterone suppression in most advanced regimens. | Drug dependent. | Major survival benefit in advanced disease but additional drug-specific toxicity. |
Key Points
- Androgen deprivation therapy lowers testosterone or removes the main testicular androgen signal used by prostate cancer.
- Do not optimize or interpret the ambiguous abbreviation “ADT” outside the prostate-cancer context; the canonical concept is androgen deprivation therapy for prostate cancer.
- Current EAU guidance prefers profound testosterone suppression below 20 ng/dL when achievable, while the historical castration definition remains below 50 ng/dL.
- GnRH agonists can cause an initial testosterone flare before suppression.
- GnRH antagonists suppress testosterone rapidly without flare.
- Bilateral orchiectomy achieves rapid permanent testosterone suppression and is irreversible.
- Relugolix is an oral GnRH antagonist; degarelix is an injectable antagonist.
- In HERO, sustained castration was 96.7% with relugolix versus 88.8% with leuprolide.
- HERO also showed faster testosterone recovery after relugolix discontinuation in its recovery subgroup.
- Androgen deprivation is not routine monotherapy for low-risk localized prostate cancer.
- Unfavorable intermediate-risk radiation commonly uses about 4–6 months of androgen deprivation.
- High-risk radiation generally uses long-course androgen deprivation, commonly about 18–36 months or 2–3 years depending on the guideline framework.
- In metastatic hormone-sensitive disease, androgen deprivation remains the hormonal backbone but fit patients generally need treatment intensification beyond monotherapy.
- Castration-resistant prostate cancer means progression despite ongoing castrate testosterone.
- Common side effects include loss of libido, erectile dysfunction, hot flashes, fatigue, muscle loss, fat gain and metabolic changes.
- Long-term therapy increases osteoporosis and fracture risk, so baseline bone-density assessment is important.
- Lipids, HbA1c/glucose, cardiovascular risk, hemoglobin and other laboratory parameters should be monitored during long-term therapy.
- Exercise combining resistance and aerobic training is an important toxicity-mitigation strategy.
- PSA response does not prove adequate testosterone suppression; serum testosterone should also be measured.
- EAU recommends clinical follow-up approximately every 3–6 months after treatment initiation, individualized to stage and regimen.
- Testosterone recovery after temporary treatment is highly variable and becomes less complete and slower as treatment duration increases.
Clinical bottom line: androgen deprivation therapy is the hormonal backbone of prostate-cancer treatment when testosterone suppression is clinically useful, but its purpose changes with disease state. With definitive radiation, it may be given temporarily to improve cancer control; in metastatic disease, it is usually continuous and combined with additional life-prolonging systemic therapy in fit patients. GnRH agonists, GnRH antagonists and orchiectomy can all achieve castrate testosterone, but they differ in speed, flare risk, route, reversibility and practical burden. The treatment affects the entire body, not just the prostate: sexual function, bone, muscle, fat, glucose metabolism, cardiovascular risk, blood counts, mood and energy all require attention. High-quality care therefore means choosing the right duration, confirming testosterone suppression, protecting bone and metabolic health, maintaining physical function and recognizing that testosterone recovery after a “temporary” course may take months or years.
Medical disclaimer: This article provides general medical education about androgen deprivation therapy for prostate cancer. The indication, drug class, route, duration, use with radiation, need for treatment intensification, cardiovascular considerations, bone protection and follow-up depend on cancer stage, Grade Group, PSA kinetics, metastatic burden, symptoms, prior treatment, life expectancy, comorbidity, medications and patient preferences. Individual treatment should be planned with the treating urology, radiation oncology and/or medical oncology team.
For the overall management framework, return to Prostate Cancer Treatment. The preceding local-radiation guide covers Brachytherapy for Prostate Cancer. The next guide reviews Prostate Cancer Treatment Side Effects across surgery, radiation and systemic therapy. Long-term monitoring and recovery are covered in Prostate Cancer Survivorship. For the broader disease framework, return to the Prostate Cancer hub.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: castrate testosterone targets, orchiectomy, GnRH agonists/antagonists, flare, cardiovascular considerations and treatment intensification in metastatic hormone-sensitive disease.
- European Association of Urology — Prostate Cancer Follow-up: PSA/testosterone monitoring, three- to six-month follow-up, bone density, metabolic monitoring and definition of castration-resistant disease.
- European Association of Urology — Quality of Life Outcomes: testosterone recovery, intermittent versus continuous treatment, bone protection and long-term androgen-deprivation toxicity.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: androgen biology, GnRH agonists/antagonists, orchiectomy, androgen-receptor blockers and common side effects.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Health Professional Version: hormonal treatment indications, complications and advanced-disease evidence.
- HERO phase III trial — oral relugolix versus leuprolide, including sustained castration, rapid suppression and major adverse cardiovascular-event results.
- HERO testosterone-recovery analysis — recovery to >280 ng/dL after relugolix versus leuprolide discontinuation.
- Systematic review of randomized trials — cardiovascular events with GnRH antagonists versus agonists, including limitations of the available cardiovascular evidence.
- ESMO 2026 advanced/metastatic prostate-cancer guideline — exercise, bone-density and supportive-care recommendations for patients receiving androgen deprivation therapy.
